Saturday, July 11, 2026

Drug profile · INN

tolazoline hydrochloride

tolazoline hydrochloride (PRISCOLINE) is a adrenergic receptor alpha antagonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — tolazoline hydrochloride
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

tolazoline hydrochloride (PRISCOLINE) is a adrenergic receptor alpha antagonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN tolazoline hydrochloride
Brand PRISCOLINE
Mechanism Adrenergic receptor alpha antagonist
Target Adrenergic receptor alpha
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Adrenergic receptor alpha antagonist

Primary target: Adrenergic receptor alpha

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. brimonidine tartrate Adrenergic receptor alpha-2 agonist
  2. carvedilol Adrenergic receptor beta antagonist
  3. clonidine hydrochloride Adrenergic receptor alpha-2 agonist
  4. dexmedetomidine hydrochloride Adrenergic receptor alpha-2 agonist
  5. doxazosin mesylate Adrenergic receptor alpha-1 antagonist
  6. guanfacine hydrochloride Adrenergic receptor alpha-2 agonist

Frequently asked questions

What is tolazoline hydrochloride?

tolazoline hydrochloride (PRISCOLINE) is a adrenergic receptor alpha antagonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for tolazoline hydrochloride?

PRISCOLINE is a marketed brand name for tolazoline hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tolazoline hydrochloride?

tolazoline hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.